Details for Patent: 9,345,772

Which drugs does patent 9,345,772 protect, and when does it expire?

Patent 9,345,772 protects ERMEZA and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 9,345,772

Patent landscape, scope, and claims:

Title:	Liquid levothyroxine formulations
Abstract:	Embodiments of the present invention provide levothyroxine solutions that consist of from about 0.001% w/v to about 0.01% w/v of a levothyroxine; at least 70% w/w of a glycerol; less than 30% w/w of a water; and from about 0.01% w/w to about 1.5% w/w of an ethylenediaminetetraacetic acid (EDTA). Such levothyroxine solutions are characterized by exhibiting levothyroxine storage stability.
Inventor(s):	Parikh; Nilesh (Irvine, CA), Hite; William (Winchester, CA)
Assignee:
Application Number:	14/634,452
Patent Claim Types: see list of patent claims	Formulation; Compound;

Drugs Protected by US Patent 9,345,772

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mylan	ERMEZA	levothyroxine sodium	SOLUTION;ORAL	215809-001	Apr 29, 2022		RX	Yes	Yes	9,345,772		Y

International Family Members for US Patent 9,345,772

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3261676
Spain	2814129
Croatia	P20201354